Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy
Paclitaxel is an active antitumor agent that has demonstrated a broad range of activity in
preclinical and clinical studies. The optimal dose and schedule has not yet been determined
in either adults or children. The objective of this trial is to determine the maximum
tolerated dose and the toxicities of paclitaxel given as a short hour infusion in children
with refractory malignancy. In addition, the pharmacokinetics of paclitaxel given in this
way will be studied and both model-dependent and model-independent parameters will be
determined.
Interventional
Endpoint Classification: Safety Study, Primary Purpose: Treatment
United States: Federal Government
940204
NCT00001387
September 1994
July 2000
Name | Location |
---|---|
National Cancer Institute (NCI) | Bethesda, Maryland 20892 |